| Date | Title | Description |
| 15.09.2026 | Fetalix, la biotech que busca cambiar el tratamiento del dolor lumbar | Fetalix es una biotech portuguesa que busca cambiar el tratamiento del dolor lumbar que afecta ~85% de la población. Su terapia regenerativa inyectable, inspirada en tejido fetal, restaura el disco intervertebral en lugar de limitarse a tra... |
| 14.09.2026 | Pediatric Vaccines Market Expected to Reach USD 56.06 Billion by 2031 as Immunization Programs and Multivalent Vaccines Expand | Pediatric Vaccines Market Overview
According to Mordor Intelligence, the Pediatric Vaccines Market Size was valued at USD 40.24 billion in 2025 and is estimated to grow from USD 42.53 billion in 2026 to reach USD 56.06 billion by 2031, at a... |
| 10.09.2026 | PW Consulting: Global Sedative-Hypnotic Drug Market Hits $4.85B in 2025, Projected 5.85% CAGR to 2032 | Navigating the Global Sedative-Hypnotic Drug Market: Strategic Imperatives for 2026 and Beyond
The global healthcare landscape is undergoing a significant transformation, driven by an aging population, increasing prevalence of sleep disorde... |
| 03.09.2026 | This vaccine reduces risk of melanoma coming back. Can it work for other cancers? | Getting your Trinity Audio player ready...
Intismeran Autogene, a vaccine that treats melanoma, a deadly type of skin cancer, has made headlines worldwide. Recently reported results indicate that the personalized medication, taken in combin... |
| 01.09.2026 | Wall Street Enters September With 57% Hike Odds, $90 Oil, and Double-Digit Gains | By Joshua Mitchell
Published: Sep 01 2026, 6:53 AM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 25.08.2026 | Как агентный ИИ меняет роль человека в цепочках поставок | В крупной компании на обработку клиентского заказа может тратиться до двух часов. В основном это время уходит не на сами действия, а на паузы между ними: ожидание ответа, перепроверку данных, согласования.
Агентская оркестрация сокращает эт... |
| 24.08.2026 | Personalized mRNA Cancer Vaccine Clears Phase 3: Melanoma Recurrence Cut by Half | By Joseph Blake
Published: Aug 24 2026, 11:46 AM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 23.08.2026 | US Treasury Targets Yields Amid Debt Surge: Fed Independence Tested | The US Treasury initiated significant bond buybacks. It aims to lower long-term yields. This intervention followed a market sell-off. Critics fear inflation and Fed policy conflicts. The national debt sits above $40 trillion. Federal Reserv... |
| 21.08.2026 | Options Action
This sleepy sector could offer big returns, says Mike Khouw | The options market rarely gives you a gift, but it might be doing that right now.
Materials don’t generally get the headlines. The Treasury Secretary’s efforts to suppress the long-end of the rate curve are noteworthy for capturing attentio... |
| 21.08.2026 | CNA Explains: What we know about the Moderna, Merck breakthrough cancer vaccine | Listen
5 min
New: You can now listen to articles.
This audio is generated by an AI tool.
Drugmakers Moderna and Merck have scored a breakthrough with a personalised cancer vaccine that doctors hope could eventually work against many types o... |
| 21.08.2026 | CNBC Daily Open: Watching Iran’s economy; a losing game for bonds | Bessent says the U.S. likely won’t restart large-scale Iran combat, betting economic sanctions can do the job instead.
A former Iran central bank adviser disputes Trump’s “collapsing economy” claim, though the UAE’s trade cutoff could hurt.... |
| 20.08.2026 | Merck is a buy as strong cancer drug pipeline offsets Keytruda patent expiration, Morgan Stanley says | - |
| 20.08.2026 | Moderna привила инвесторам надежду | Moderna привила инвесторам надежду Насколько успешными оказались испытания вакцины от меланомы
Акции Moderna взлетели на 160% после успешных испытаний вакцины от рака. Результаты тестов вызвали фурор среди инвесторов на бирже Nasdaq — стоим... |
| 20.08.2026 | CNBC Daily Open: Treasury attempts to rein in bond yields as U.S. debt swells past $40 trillion | Treasury doubles longer dated debt purchases.
Stock markets snap a three day losing streak.
U.S. national debt crosses $40 trillion.
Trump vows the “most crushing economic operation” against countries that help Iran.
Moderna and Merck share... |
| 20.08.2026 | 5 Things to Know
The Treasury’s debt buyback, Walmart earnings, Boise’s AI boom and more in Morning Squawk | This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox.
Happy Thursday. Valentine’s Day is still six months away, but as CNBC’s Kai Nicol-Schwarz reports, Nvidia is already playing matchmaker.
Stoc... |
| 20.08.2026 | CNBC Daily Open: Trump bemoans ‘ridiculous rates’ | U.S. President Donald Trump calls interest rate levels “artificial,” saying the economy is powerful despite “ridiculous rates.”
The Treasury is taking measures to calm the bond market, as U.S. government debt tops $40 trillion.
Trump threat... |
| 20.08.2026 | Stocks waver, dollar drops as US Treasury moves to lower bond yields | NEW YORK: Stock markets mostly rose on Wednesday (Aug 19) and the dollar fell sharply after the US Treasury signalled action to push down government bond yields, easing fears that higher borrowing costs would weigh on economic growth worldw... |
| 19.08.2026 | Moderna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock more than doubles | An experimental personalized cancer vaccine from Merck and Moderna showed positive initial results in its first-ever late-stage trial.
The combination regimen met the main study goal of significantly extending the time patients lived withou... |
| 19.08.2026 | $1,000 invested in Moderna stock a week ago is now worth |
As Moderna Inc. (NASDAQ: MRNA) stock spiked sharply on August 19, catalyzed by positive late-stage trial results for its personalized mRNA (messenger ribonucleic acid) cancer vaccine; $1,000 invested in this company a week ago has more tha... |
| 19.08.2026 | Why Moderna stock is rocketing today |
Moderna (NASDAQ: MRNA) stock is rocketing in pre-market trading on Wednesday after the biotechnology company and its partner, Merck, reported positive Phase 3 results for their personalized mRNA-based cancer vaccine for melanoma.
Notably, ... |
| 19.08.2026 | Moderna shares surge after it says its experimental mRNA cancer treatment passed a key test | Getting your Trinity Audio player ready...
By The Associated Press
Moderna shares more than doubled Wednesday after it announced initial results from a study of an experimental cancer treatment that would be the first of its kind if approve... |
| 19.08.2026 | US stocks look to halt their 3-day slide as pressure from the bond market eases | Getting your Trinity Audio player ready...
By STAN CHOE, AP Business Writer
NEW YORK (AP) — U.S. stocks are ticking higher Wednesday after the U.S. Treasury Department said it will buy more U.S. government bonds in a move that eased pressur... |
| 19.08.2026 | Daily Stock Market Live
Dow tumbles 700 points, S&P 500 falls as Treasury plan to subdue yields fails | U.S. stocks fell as Treasury yields continued their march higher despite the Treasury Department’s extraordinary debt buyback operation, raising concerns that higher borrowing costs will throw a wrench into the bull market.
The Dow Jones In... |
| 19.08.2026 | 5 Things to Know
Target earnings, Canada tariffs, American Airlines’ seatback screens and more in Morning Squawk | This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox.
Happy Wednesday. Shares of Moderna soared as much as 100% before the bell after the experimental personalized cancer vaccine it developed wit... |
| 18.08.2026 | Daily Stock Market Live
Dow rises as Treasury unveils plan to relieve bond market pressure: Live updates | The Dow Jones Industrial Average rose on Wednesday as bond yields fell following the Treasury Department’s announcement of an increased buyback operation for longer-term debt.
The 30-stock Dow added 209 points, or 0.4%. The S&P 500 trad... |
| 16.08.2026 | Infinimmune Secures $75M to Propel Human Antibody Therapeutics | Infinimmune secures $75 million in Series A funding. This capital fuels the company's human-first antibody pipeline. Lead candidates target atopic dermatitis. Clinical trials for these programs are expected in 2027. Regeneron Ventures and P... |
| 14.08.2026 | Pharmaceuticals Market Trends: Innovation, Rising Healthcare Demand, and Advanced Therapies Driving Growth | The pharmaceuticals market is witnessing strong growth as rising healthcare needs, increasing disease prevalence, expanding access to medicines, and continuous innovation in drug development drive global demand. Pharmaceutical products play... |
| 12.08.2026 | Silent Cancer Therapeutics Market Size to Reach USD 36.52 Billion by 2035, Driven by Precision Oncology and Advanced Cancer Therapies | Overview
According to DataM Intelligence, the global silent cancer therapeutics market size was valued at USD 15.86 billion in 2025 and is forecast to reach USD 36.52 billion by 2035, expanding at a CAGR of 8.7% during 2026 to 2035. The mar... |
| 11.08.2026 | Infinimmune Raises $75M To Advance Human Antibody Pipeline | Infinimmune Raises $75M For Clinical Development
Infinimmune has raised $75 million in Series A funding to advance its antibody therapeutics pipeline. The financing was co-led by Regeneron Ventures and Playground Global.
Several new and exi... |
| 11.08.2026 | ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer | ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the appointments of Jim Wassil, currently Chief Operating Off... |
| 11.08.2026 | Trump wants to split the MMR vaccine. Experts say that’s unlikely — and comes with consequences | President Donald Trump’s latest executive order calls for splitting the measles, mumps and rubella, or MMR, vaccine into three separate shots.
But doctors and other experts say that effort has no scientific basis and is unlikely to get off ... |
| 07.08.2026 | Stanford is running 37,000 AI agents as a virtual biotech — and one of its drug designs got independently confirmed by Merck | For developers, the operating assumption has been one engineer, one agent — the model Claude Code and similar tools. At VB Transform 2026, James Zou, associate professor of biomedical data science at Stanford University, argued that assumpt... |
| 06.08.2026 | I'm an 80-year-old widow who sold my home and moved into a retirement community. I'm less stressed and don't feel managed. | This as-told-to essay is based on a conversation with Rose Marie Obey, an 80-year-old widow living in a retirement community in Ambler, Pennsylvania. The following has been edited for length and clarity.
After my husband of 54 years, Lee, d... |
| 04.08.2026 | BioNTech Slashes 2026 Revenue Guidance by €700M as COVID Vaccine Sales Crater | By Brandi Henkel
Published: Aug 04 2026, 2:28 PM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 04.08.2026 | Merck hikes revenue outlook as new drug sales grow, but cuts profit guidance due to deal charges | Merck beat second-quarter estimates and hiked its revenue outlook, as a slate of new products showed strong growth.
But the pharmaceutical giant cut its profit guidance due to a charge tied to its acquisition of biotech company Terns Pharma... |
| 04.08.2026 | Stocks making the biggest moves premarket: McDonald’s, Caterpillar, Palantir, Merck & more | - |
| 03.08.2026 | Daily Stock Market Live
Dow futures jump 400 points after strong Caterpillar and Palantir earnings, S&P 500 to make run at record: Live updates | Stock futures moved higher on Tuesday, fueled by strong quarterly results from companies such as Caterpillar and Palantir Technologies.
Nasdaq-100 futures popped about 1%, as Palantir rallied more than 15% in premarket trading on blowout re... |
| 31.07.2026 | Moderna Norovirus Vaccine Fails Interim Bar: Trial Extends Into Fourth Season | By Collin Mercer
Published: Jul 31 2026, 9:16 AM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 31.07.2026 | Datroway approved in EU for TNBC | Datroway approved in EU for TNBC
Fri, Jul 31, 2026 08:48 CET Report this content
31 July 2026
Datroway approved in the EU as only TROP2-directed medicine with overall survival benefit for the 1st-line treatment of patients with metastatic T... |
| 30.07.2026 | NMPA Accepts New Indication Application for Sacituzumab Tirumotecan (sac-TMT) as First-Line Treatment for Advanced TNBC | CHENGDU, China, July 30, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that a new indication application of its trophoblast cell-surface anti... |
| 28.07.2026 | Sweeping job cuts at GSK to fund £400m Cambridge campus | GSK is poised to slash its back office headcount to help fund a £400m mega-campus in Cambridge, in a move it hopes will bolster its drugs pipeline anFd stave off a looming patent cliff-edge.
In his first major update as chief executive, Luk... |
| 28.07.2026 | New Cholesterol Rules Add 21.5 Million Americans to Statin Eligibility List | By Jackie Manning
Published: Jul 28 2026, 8:46 PM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 27.07.2026 | PEPFAR Cuts Left 77,000 Fewer Children on HIV Treatment as AIDS 2026 Opens in Rio | By Jackie Manning
Published: Jul 27 2026, 12:36 PM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 20.07.2026 | Marengo Secures ESMO 2026 Oral Presentation for Key Phase 2 Invikafusp Alfa Data in PD-1–Resistant Solid Tumors and Appoints Pembrolizumab Development Leader Eric Rubin, M.D., to Scientific Advisory B... | Updated STARt-001 results will highlight invikafusp alfa's single-agent activity in PD-1–resistant tumors using a biomarker-enrichment strategy
Eric Rubin, former Senior Vice President of Global Clinical Oncology at Merck, who led the initi... |
| 16.07.2026 | Merck’s Lipfendra Becomes First Oral Cholesterol Pill to Match Injectable PCSK9 Potency | By Luke McKenzie
Published: Jul 16 2026, 10:49 AM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 16.07.2026 | FDA approves a first-of-its-kind pill to cut cholesterol in high-risk patients | Getting your Trinity Audio player ready...
By MATTHEW PERRONE, AP Health Writer
WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-its-kind pill that can drastically reduce cholesterol in a way that’s previously only... |
| 15.07.2026 | Kelun-Biotech Announces Phase III Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Met Primary Endpoint | As a head-to-head Phase III trial comparing sac-TMT plus pembrolizumab with the first-line standard of care (immunotherapy plus chemotherapy), OptiTROP-Lung06 demonstrated the superiority of replacing conventional pemetrexed/platinum chemot... |
| 09.07.2026 | Immunotherapy Drugs Market to Reach $580.6 Billion by 2029 | The global Immunotherapy drugs market is projected to grow from USD 285.3 billion in 2024 to USD 580.6 billion by 2029, at a robust CAGR of 15.3% during the forecast period. Market growth is driven by advancements in antibody engineering te... |
| 01.07.2026 |
Jim Cramer says this former Covid market darling is finally investable again | Monday - Friday, 6:00 - 7:00 PM ET
CNBC’s Jim Cramer said Moderna has evolved beyond its Covid-era business, arguing the biotech company’s expanding pipeline in treatments for cancer and other diseases provides a compelling long-term invest... |
| 30.06.2026 | Stocks making the biggest moves premarket: AeroVironment, Strategy, Merck & more | - |
| 23.06.2026 | Portal Biotechnologies Secures $9 Million for Cell Engineering Expansion | Portal Biotechnologies landed $9 million. This funding round, led by NFX, will propel commercial scaling of its cell engineering and drug discovery platform. The company's proprietary mechanoporation technology efficiently delivers complex ... |
| 22.06.2026 | Daily Stock Market Live
S&P 500 falls on global chip rout with Nasdaq off 2%, led by Micron: Live updates | The S&P 500 was lower on Tuesday as a tech sell-off that began during the prior session picked up steam overnight, with global markets in Asia routed as memory chip-related shares tumbled.
The broad market index fell 1.3%, while the Nas... |
| 22.06.2026 | Translational Research Results of Sacituzumab Tirumotecan (sac-TMT) in Combination with Osimertinib as First-Line Treatment for EGFR-Mutant NSCLC Published in Cancer Cell | — The study shows that EGFR-TKIs induce TROP2 upregulation in DTP cells, providing a mechanistic basis for combining sac-TMT with EGFR-TKI.
— The Company is conducting a Phase III registrational study of sac-TMT plus osimertinib as first-li... |
| 18.06.2026 | Portal Biotechnologies Raises $9 Million To Expand Cell Engineering Platform | Portal Biotechnologies announced the closing of an oversubscribed $9 million financing round. The round was led by NFX, with participation from existing investors including IA Ventures, Pear VC, Undeterred Ventures, IKJ Capital, and TechU V... |
| 18.06.2026 | FDA Clears CAPVAXIVE for Chronically Ill Children: Vaccine Covers 11 Strains Rivals Miss | By Maxwell Templeton
Published: Jun 18 2026, 09:38 AM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 16.06.2026 | Colorado receives FDA permission to import cheaper drugs — including Ozempic — from Canada | Getting your Trinity Audio player ready...
Colorado finally has federal permission to start importing cheaper prescription drugs from Canada, but the state may not have any sellers to work with.
Lawmakers passed a bill in 2019 that directed... |
| 15.06.2026 | Rajashiva Ramalingam Built the Mobile Layer That Enterprise Freight Tracking Was Missing | Share
Share
Share
Share
Email
While enterprise transportation systems sat blind to what was happening on the road, an SAP engineer at ITC Infotech identified the gap, designed a solution, and brought it to market as a commercial product bef... |
| 09.06.2026 | PDA Announces Glenn E. Wright is Stepping Down as CEO & President on June 30, 2026; Craig Elliott Assuming Role Effective July 1, 2026 | After 37 years of dedicated service to PDA and its members, Glenn E. Wright steps down as President & CEO effective June 30, 2026. Craig Elliott has been selected by the Board of Directors to fill the role starting July 1.
BETHESDA, Md.... |
| 31.05.2026 | A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China | An experimental lung cancer drug from Akeso and Summit Therapeutics improved survival in the Harmoni-6 Phase 3 trial conducted in China, according to results being presented at the American Society of Clinical Oncology annual meeting.
Calle... |
| 31.05.2026 | Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet | CHENGDU, China, May 31, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced today that the results of the Phase III clinical study OptiTROP-Lung05, evaluating the company's tro... |
| 30.05.2026 | The Results of Phase III OptiTROP-Lung05 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ASCO Oral Presentation and Simultaneously Published in The Lancet | CHENGDU, China, May 30, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced today that at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, the r... |
| 29.05.2026 |
Jim Cramer says Dell’s blowout quarter sets up a crucial week for AI stocks | Monday - Friday, 6:00 - 7:00 PM ET
CNBC’s Jim Cramer said Dell Technologies’ blockbuster quarter reignited enthusiasm around AI and data center stocks, while next week could bring fresh clarity for lagging Nvidia.
He highlighted upcoming re... |
| 28.05.2026 | Real Chemistry Appoints Healthcare Industry Leaders Frank Clyburn and Chris Fikry to Board of Directors | Real Chemistry, a leader in AI-driven insights and marketing and communications exclusively for the healthcare and life sciences sectors, today announced the appointments of two non-executive board members, Frank Clyburn and Christopher (Ch... |
| 27.05.2026 | Merck and Mastercard are seeing real agentic AI results. Both say the plumbing came first. | Merck is using AI agents to cut drug discovery cycles by a third and ship compliant marketing materials up to 80% faster — but VP of Digital Platforms Sean Finnerty says the only reason it's working is because they built the infrastructure ... |
| 26.05.2026 | Camizestrant recommended for breast cancer in EU | Camizestrant recommended for breast cancer in EU
Tue, May 26, 2026 08:00 CET Report this content
26 May 2026
Camizestrant in combination with a CDK4/6 inhibitor recommended for approval in the EU by CHMP for 1st-line advanced ER-positive br... |
| 22.05.2026 | Stocks making the biggest moves premarket: IMAX, Merck, Estee Lauder & more | - |
| 22.05.2026 | Kelun-Biotech to Present Two Registrational Studies in the Oral Presentation Session on Non-Small Cell Lung Cancer at ASCO 2026 | Sacituzumab tirumotecan (sac-TMT)(佳泰莱®) plus pembrolizumab versus pembrolizumab as first-line treatment for PD-L1 positive advanced NSCLC: Results from the randomized, controlled, registrational Phase III OptiTROP-Lung05 study (Abstract #85... |
| 21.05.2026 | Synergis Software Launches Adept Cloud, a Cloud-Native Engineering Document Management Platform Built for Asset-Intensive Industries | The award-winning Adept platform, now delivered as a fully managed SaaS solution — with AI capabilities built in
QUAKERTOWN, Pa., May 21, 2026 /PRNewswire/ -- Synergis Software announced the general availability of Adept Cloud, a cloud-nati... |
| 20.05.2026 | Synergis Software Opens Adept Experience 2026 With the Largest Product Launch in Company History | Adept Cloud, Adept AI, Adept Catalyst, and the next-generation SOLIDWORKS integration headline a milestone week for the engineering document management leader
BETHLEHEM, Pa., May 20, 2026 /PRNewswire/ -- Synergis Software opened Adept Exper... |
| 08.05.2026 | The sNDA for Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First‑Line Treatment for PD-L1-positive NSCLC Accepted for Review by NMPA | CHENGDU, China, May 8, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company") announced that the sNDA (the "Application") for the Company's TROP2 ADC sacituzum... |
| 07.05.2026 | Global drugmakers eye more China biotech deals after record year | Global pharmaceutical executives are hungry for more deals with Chinese biotechnology companies after a record year, even as a stock market boom shows signs of cooling down.
2025 was a breakout year for China’s biopharma industry. Out-licen... |
| 06.05.2026 | PDA announces the 2026 PDA/FDA Joint Regulatory Conference | The Parenteral Drug Association announces the 2026 PDA/FDA Joint Regulatory Conference, at the Westin DC Downtown, September 14-16, 2026, in Washington, D.C.
BETHESDA, Md., May 6, 2026 /PRNewswire-PRWeb/ -- This premier CGMP conference spot... |
| 01.05.2026 | Jason Chambers Teams Up with the Melanoma Research Foundation to #GetNaked for Melanoma Awareness Month | The Melanoma Research Foundation (MRF) is pleased to announce the launch of its annual award-winning #GetNaked campaign recognizing the melanoma patient community during Melanoma Awareness Month. In 2026, the MRF is joined by Superyacht Cap... |
| 27.04.2026 | Ray Therapeutics Secures $125M for Advanced Vision Restoration Therapies | Ray Therapeutics closed an oversubscribed $125M Series B. The funding propels advanced optogenetic vision restoration therapies. Janus Henderson Investors led the round. Capital supports clinical development for RTx-015 (Retinitis Pigmentos... |
| 25.04.2026 | Merck signs USD $1 billion AI deal with Google Cloud | - |
| 24.04.2026 | Iridius: $8.6 Million Seed Funding Raised To Build Compliance-By-Design AI Platform For Regulated Industries | Iridius, a compliance-by-design AI platform for regulated workflow execution, has raised $8.6 million in seed funding led by Chalfen Ventures, with participation from Osage Venture Partners, Accenture Ventures, and Rock Yard Ventures. Separ... |
| 24.04.2026 | Four Swiss companies appoint new CEOs across tech and pharma |
Altoo, a Swiss wealth management platform that consolidates financial data across banking, investments and alternative holdings into a single digital interface, has appointed Achille Deodato as Chief Executive Officer. Deodato succeeds Ian... |
| 21.04.2026 | Ray Therapeutics Raises $125M in Series B Funding | Ray Therapeutics, a Berkeley, CA-based clinical-stage biopharmaceutical company developing differentiated vision restoration therapies for those living with retinal degenerations, raised $125M in Series B funding.
The round was led by Janus... |
| 08.04.2026 | Jeito Capital Hits Record $1.2 Billion (€1 Billion)1 Close for Jeito II Fund to Drive Breakthrough Therapeutic Innovation for Patients | Jeito Capital (“Jeito”), a global independent private equity fund dedicated to Biopharma, today announces the final closing of its second fund Jeito II, exceeding its target at $1.2 billion (above €1 billion)1,2, and marking a new major mil... |
| 07.04.2026 | Corporate Vision and Trade Confrontation: The Shifting U.S. Economic Narrative | Motorola Solutions CEO Greg Brown earns top honors, lauded for transforming the company into a global public safety and security technology leader. His strategic vision and operational prowess drove exceptional growth and innovation. Meanwh... |
| 06.04.2026 | Motorola Solutions' Greg Brown Is Chief Executive Magazine's 2026 CEO of the Year | Chief Executive magazine announced Motorola Solutions Chairman and CEO Greg Brown as 2026 Chief Executive of the Year, recognizing his leadership in transforming the company into a leading safety and security technology provider and deliver... |
| 06.04.2026 | Biotech Firm Gets a New Leader
New chief chosen | - |
| 03.04.2026 | Declining patent filings show Britain has stopped innovating | There are lots of ways to measure innovation, but if we go by patent filings, it’s a sorry image for the UK, writes Ayushma Maharjan
Britain’s days as the home of the Industrial Revolution are long gone. But many people still cling to the n... |
| 29.03.2026 | Back-up care benefits at work go beyond kids, aging parents as more employers pay for pets | Back-up care benefits companies like Wellthy and Bright Horizons now include pets in their programs, alongside children and elderly family members.
Wellthy first began offering pet back-up care in 2024 and added its “Pet Care Concierge” las... |
| 27.03.2026 | Global Crossroads: Pharma Shifts and Markets Sway | Wall Street navigates intense volatility. Geopolitical tensions from the ongoing Iran conflict drive market swings. Oil prices ease on perceived de-escalation, yet regional attacks persist. Global stocks post fragile gains. Amid this turbul... |
| 27.03.2026 | Novartis shells out $2 billion for immunology biotech Excellergy, in second multi-billion dollar deal in a week | Novartis’ acquisition of U.S.-based Excellergy will add an early-stage drug candidate Exl-111 to the company’s existing allergy portfolio.
It comes just a week after Novartis announced it is acquiring Synnovation subsidiary Pikavation Thera... |
| 25.03.2026 | Stocks rise and oil prices ease as Wall Street keeps yo-yoing because of the war with Iran | Getting your Trinity Audio player ready...
By STAN CHOE, AP Business Writer
NEW YORK (AP) — Hopes for a possible end to the war with Iran pushed stocks higher on Wall Street Wednesday, while oil prices eased. Related Articles
Europe’s top c... |
| 25.03.2026 | 5 Things to Know
U.S.-Iran negotiations, Meta trial verdict, OpenAI shuts Sora and more in Morning Squawk | This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox.
Happy Wednesday. I spent yesterday evening at a market technicals event and then went to watch the “Hannah Montana 20th Anniversary Special.”... |
| 25.03.2026 | Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipeline | Merck will acquire Terns for $53 per share in cash, amounting to an equity value of about $6.7 billion.
This is the third multibillion-dollar acquisition for Merck over the past year as it looks to bulk up its portfolio ahead of its best-se... |
| 24.03.2026 | WuXi Biologics Reports Record 2025 Annual Results | Revenue increased 16.7% YoY to RMB 21.8 billion, and revenue from continuous operations grew over 20% YoY
IFRS gross profit margin expanded to 46.0% (+500 bps YoY); adjusted gross profit margin increased to 48.8% (+340bps)
EBITDA rose 38.1%... |
| 23.03.2026 | Investors eye farming as AI’s latest cash cow | A startup fitting livestock with AI-powered collars is closing in on a $2bn valuation, as investors turn their attention to a less obvious frontier for AI.
New Zealand-based Halter is in talks to raise fresh funding led by Founders Fund, th... |
| 21.03.2026 | Biotech Powerhouse Mestag Therapeutics Secures $40M for Advanced Therapies | Mestag Therapeutics has secured $40 million in new financing. This pushes its total funding past $95 million. The Cambridge-based biotech fuels its Phase 1 STARLYS clinical trial for cancer drug MST-0312. This pivotal trial begins in mid-20... |
| 19.03.2026 | Moon Rabbit Appoints Loren Levinson EVP, Executive Strategy Director | Leadership addition expands agency's strategy capabilities amid continued growth
NEW YORK, March 19, 2026 /PRNewswire-PRWeb/ -- Moon Rabbit, an independent advertising and marketing agency focused on pharma and healthcare, today announced t... |
| 19.03.2026 | Harbour BioMed Appoints Dr. Jenny Xie as Chief Scientific Officer, Immunology and Head of Global External Innovation | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 19, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody thera... |
| 19.03.2026 | Bambusa Therapeutics Appoints Todd James Chief Financial Officer | - Mr. James brings more than 20 years of biopharmaceutical leadership experience, with deep expertise in capital markets, investor relations, and corporate strategy, serving in senior executive roles at Acceleron Pharma prior to its $11.5 b... |
| 18.03.2026 | Kelun-Biotech to Present the Final OS Analysis of Sacituzumab Tirumotecan (Sac-TMT) from the OptiTROP-Lung03 Study | CHENGDU, China, March 18, 2026 /PRNewswire/ -- The 2026 European Lung Cancer Congress (ELCC) will be held in Copenhagen, Denmark, from March 25 to 28, 2026 (local time). At this congress, the final OS analysis from the pivotal study (OptiTR... |
| 17.03.2026 | Mestag Therapeutics Raises $40M in Financing | Mestag Therapeutics, a Cambridge, UK-based biotech company harnessing fibroblast immunology to develop treatments for cancer and inflammatory diseases, closed a $40m financing.
Backers includwed SV Health Investors, Johnson & Johnson, t... |
| 13.03.2026 | These stocks will benefit from AI and an aging population, Jefferies says. They also pay dividends | - |
| 12.03.2026 | Nuance Pharma Announces Approval of Ohtuvayre® (ensifentrine) in Hong Kong SAR, China | Approval marks the second regulatory approval outside of the U.S. Food and Drug Administration, further expanding access to COPD patients in select Special Administrative Regions (SARs) in Greater China
SHANGHAI, March 12, 2026 /PRNewswire/... |
| 10.03.2026 | Bright spots in tackling AMRs, but drug-resistance outpaces pharma industry efforts: Report | - |
